A NEW Phase 3 trial has shown that a combination therapy of cagrilintide and semaglutide (CagriSema) can lead to substantial weight loss and improved glycaemic control in adults with Type 2 diabetes and overweight or obesity
The regulator emphasized that patient safety remains paramount
Book Your Consultation for Tirzepatide Therapy Today
Regular meal timing : Eating at consistent intervals prevents excessive hunger that can trigger intense sugar cravings
Identifying Suitable Candidates for Semaglutide Potential candidates for a semaglutide weight loss program should ideally have a BMI of 30 or above, or 27 with conditions such as high blood pressure, type 2 diabetes, or high cholesterol
Vitrag Shah Physician & Intensivist Vitrag Hospital, Pal-Adajan, Surat #drvitragshah #HealthTalks #WeightLoss #Mounjaro #Wegovy #ObesityCare #WeightManagement #DiabetesCare #HealthyLiving #PatientEducation #HealthcareAwareness #Physician #Intensivist #VitragHospital #CriticalCare #Tirzepatide #Semaglutide #ObesityDrugs | Dr Vitrag Shah - Critical Care Specialist & Physician